SKYCovione from SK Bioscience Co. - first WHO-backed COVID-19 vaccine from Korea

Reviewed: ad hoc news Classics & Longseller desk. Edited and checked on 2026-06-28, 03:07. Details in the imprint.

SKYCovione from SK Bioscience looks deceptively simple in the nurse's gloved hand, a clear liquid in a small vial, but for many patients it has become the quiet routine shot that still keeps COVID-19 at bay years after the first pandemic shock.

What SKYCovione actually is

SKYCovione is a protein subunit COVID-19 vaccine that uses a recombinant spike protein, assembled into nanoparticles to trigger an immune response without live virus. Patients do not see the nanoparticles, of course, but they feel the familiar sting in the upper arm and the mild ache that can follow.

Developed together with the Institute for Protein Design at the University of Washington, SKYCovione builds on a novel nanoparticle platform that presents the virus spike protein repeatedly to the immune system, aiming for a robust and tidy antibody response. In everyday clinic use, doctors appreciate that the shot behaves like other protein vaccines, with storage requirements more forgiving than deep-freeze mRNA logistics.

How it earned global backing

SK Bioscience chief executive Ahn Jae-yong has repeatedly framed SKYCovione as a strategic move to give Korea its own COVID-19 vaccine rather than relying entirely on imports, and that narrative resonated with local health authorities when the vaccine received domestic approval. In press photos, Ahn stands next to rows of vials and cold-chain boxes, a concrete reminder that this is a product, not just a concept.

Internationally, SKYCovione attracted support from the Coalition for Epidemic Preparedness Innovations (CEPI), which funded parts of the development and clinical trials with the aim of supplying COVAX and other global health programs. That backing gave SK Bioscience leverage to position the vaccine for lower- and middle-income countries that still prefer protein-based platforms over newer technologies when it comes to long-term immunization campaigns.

Practical handling in clinics

Nurses like Kim Ji-eun at a public health center in Seoul describe SKYCovione as a "straightforward" vaccine to work with, not least because it can be stored in normal refrigeration rather than deep-frozen conditions. Vials line up in standard fridges beside influenza shots, and the workflow stays familiar even when booster campaigns pick up.

For patients, that practicality translates into shorter waiting times and fewer cancelled appointments due to cold-chain hiccups. The injection itself feels similar to a flu shot, with a sharp but brief needle sensation followed by the arm heaviness that many people now recognize as a sign their immune system is busy.

Position among other COVID-19 vaccines

Compared with mRNA vaccines from global giants, SKYCovione plays in a quieter corner of the market, where some regulators and doctors still favor protein-based platforms for their track record and perceived safety profile. SK Bioscience leans into that niche, presenting SKYCovione as part of a broader portfolio that includes vaccines against influenza and other diseases.

In Korea, the vaccine slots into national immunization strategies as one option among several, often used in catch-up campaigns or for people who cannot or do not want to receive mRNA shots. That role may be modest in absolute numbers but creates a steady, recurring demand as COVID-19 transitions into an endemic respiratory disease.

Where it shines and where it lags

One consistent strength of SKYCovione is that it fits into existing vaccine infrastructure with minimal disruption. Hospital pharmacists do not need special freezers, and logistics teams can piggyback on standard vaccine distribution routes, which cuts complexity and supports consistent delivery even in regional clinics.

The flip side is that, as a first-generation COVID-19 vaccine, SKYCovione faces competition from updated formulations that target newer variants and combine multiple strains. SK Bioscience therefore has to decide whether to invest in variant-updated versions of this platform or to shift resources into next-wave vaccines using different technologies.

What this means for SK Bioscience shares

SK Bioscience used SKYCovione to establish itself as a serious player in the global vaccine business, a position that still matters in pipeline discussions and partnership talks. On the Korea Exchange, SK Bioscience shares (ISIN KR7326030004) continue to reflect investor expectations about how far products like SKYCovione can carry growth beyond the pandemic years.

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.

en | KR7326030004 | SK BIOSCIENCE | boerse | 69643101 | bgmi